Information Library
Clinical and marketing materials - Market Access
To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.
- Sort by: Most Recent
- Title
-
Orphan Drugs in the U.S.
June 24, 2009
Presentation by Dr. John Doyle, Market Access Practice Leader, from ISPOR 14th Annual International Meeting 2009(International Society for Pharmacoeconomics and Outcomes Research) on “Orphan Drugs' Market Access in the U.S.” -
Harnessing a Speciality Salesforce
March 26, 2009
NovaQuest’s predecessor, PharmaBio Development, committed more than $400 million in milestone payments and sales force services to fund the launch of Cymbalta and support commercialization efforts for five years. A dedicated service company created by PharmaBio Development is providing more than 500 Innovex sales representatives to supplement the extensive Lilly primary care and specialty sales forces. -
James C. Kirk
March 25, 2009
Jim joined Eidetics in 1988 from senior management positions in consumer and industrial product marketing, strategy, and development positions at Ocean Spray Cranberries and Gillette Company. Previously at Ocean Spray, Jim successfully spearheaded the company’s new Ingredient Division. -
John Doyle, Dr. PH
March 25, 2009
John was president and a founder of Analytica International a global reimbursement, outcomes and market access consulting firm. He previously led the Oncology and Immunology Economics Research Group at Bristol-Myers Squibb. -
A New Gold Standard for Pricing
September 26, 2008
Dr. John Doyle, practice leader for market access at Quintiles Consulting, introduces the concept of a health economic balance sheet and evidence-based pricing for biopharmaceutical valuation.
Page 1 of 1 (5 items)